Dynavax Raises $44 Million Through Public Offering of Common Stock and Warrants
April 13, 2010 06:18 ET
|
Dynavax Technologies
BERKELEY, CA--(Marketwire - April 13, 2010) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the pricing of an underwritten offering resulting in gross proceeds of $44 million, before...
Dynavax Announces New Employment Inducement Awards
April 09, 2010 19:09 ET
|
Dynavax Technologies Corporation
BERKELEY, CA--(Marketwire - April 9, 2010) - Dynavax Technologies Corporation (NASDAQ: DVAX) reported that equity awards were made to two new employees under the Company's 2010 Employment...
Dynavax Reports Positive Findings From Detailed Safety Analysis of HEPLISAV(TM)
March 23, 2010 06:00 ET
|
Dynavax Technologies
BERKELEY, CA--(Marketwire - March 23, 2010) - Dynavax Technologies Corporation (NASDAQ: DVAX) will present for the first time a detailed analysis of safety data for HEPLISAV™, an...
Dynavax Anticipates Earlier BLA Submission for HEPLISAV(TM)
March 16, 2010 08:00 ET
|
Dynavax Technologies
BERKELEY, CA--(Marketwire - March 16, 2010) - Dynavax Technologies Corporation (NASDAQ: DVAX) today said that its large-scale Phase 3 study of HEPLISAV™ is
fully enrolled, with immunization of...
Dynavax and Merck Agree on Final Reimbursements
March 15, 2010 06:00 ET
|
Dynavax Technologies
BERKELEY, CA--(Marketwire - March 15, 2010) - Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the successful completion of negotiations relating to Merck's reimbursement...
Dynavax Selects Clinical Candidate in Universal Flu Vaccine Program
February 25, 2010 06:00 ET
|
Dynavax Technologies
BERKELEY, CA--(Marketwire - February 25, 2010) - Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it has selected a clinical vaccine candidate for its novel Universal Flu...
Dynavax and GlaxoSmithKline Select Clinical Candidate in the Endosomal TLR Inhibitor Program
February 18, 2010 06:00 ET
|
Dynavax Technologies
BERKELEY, CA--(Marketwire - February 18, 2010) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the selection of a candidate for clinical development in its endosomal Toll-like...
Dynavax Receives Canadian Approval to Conduct Phase 3 Trials of HEPLISAV(TM)
February 16, 2010 16:15 ET
|
Dynavax Technologies
BERKELEY, CA--(Marketwire - February 16, 2010) - Dynavax Technologies Corporation (NASDAQ: DVAX) announced that Health Canada, the Canadian equivalent of the U.S.
Food and Drug Administration, has...
Dynavax Initiates Large-Scale Phase 3 Trial of HEPLISAV(TM)
February 08, 2010 16:15 ET
|
Dynavax Technologies
BERKELEY, CA--(Marketwire - February 8, 2010) - Dynavax Technologies Corporation (NASDAQ: DVAX) announced today initiation of a large-scale Phase 3 trial designed to
demonstrate the lot-to-lot...
Dynavax Reports Positive Phase 1b Data for SD-101 in Chronic Hepatitis C Infection
January 26, 2010 06:00 ET
|
Dynavax Technologies Corporation
BERKELEY, CA--(Marketwire - January 26, 2010) - Dynavax Technologies Corporation (NASDAQ: DVAX) announced today data from two studies that differentiate SD-101 from
standard-of-care as well as...